|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer显示文摘Epithelial ovarian cancer(OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer(ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies. | José Antonio López-Guerrero Ignacio Romero Andrés Poveda | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 2 | Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic ( COL1A1-PDGFB ), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors显示文摘 | Beatriz Llombart Carlos Monteagudo Onofre Sanmartín José Antonio López-Guerrero Carlos Serra-Guillén Andrés Poveda Esperanza Jorda Antonio Fernandez-Serra Antonio Pellín Carlos Guillén Antonio Llombart-Bosch | 2010 | Journal of the American Academy of Dermatology2010，，3： | 1 |
| 3 | Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients显示文摘Although it is assumed that the combination of chemotherapy and radical surgery should be indicated in all newly diagnosed advanced-stage ovarian cancer patients, one of the main raised questions is how to select the best strategy of initial treatment in this group of patients, neoadjuvant chemotherapy followed by interval debulking surgery or primary debulking surgery followed by adjuvant chemotherapy. The selection criteria to offer one strategy over the other as well as a stepwise patient selection for initial treatment are described. Selecting the best strategy of treatment in newly diagnosed advanced stage ovarian cancer patients is a multifactorial and multidisciplinary decision. Several factors should be taken into consideration:(1) the disease factor, related to the extension and localization of the disease as well as tumor biology;(2) the patient factor, associated with patient age, poor performance status, and co-morbidities; and(3) institutional infrastructure factor, related to the lack of prolonged operative time, an appropriate surgical armamentarium, as well as well-equipped intensive care units with well-trained personnel. | Lucas Minig Cristina Zorrero Pablo Padilla Iserte Andres Poveda | 2015 | World Journal of Methodology2015，5，4： | 1 |
| 4 | Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone显示文摘 | Carolyn N. Krasner Andres Poveda Thomas J. Herzog Jan B. Vermorken Stanley B. Kaye Antonio Nieto Pilar Lardelli Claret Youn Choi Park Trilok Parekh Bradley J. Monk | 2012 | Gynecologic Oncology2012，，1： | 1 |
| 5 | Effect of Permanent Atrial Fibrillation on Cognitive Function in Patients With Chronic Heart Failure显示文摘 | Maria Coma Maria Jesús González-Moneo Cristina Enjuanes Paula Poveda Velázquez Deva Bas Espargaró Bernardo Andrés Pérez Marta Tajes Anna Garcia-Elias Núria Farré Gonzalo Sánchez-Benavides Julio Martí-Almor Josep Comin-Colet Bego?a Benito | 2015 | The American Journal of Cardiology2015，，： | 1 |
| 6 | 奥拉帕利维持治疗BRCA 1/2突变铂敏感复发性卵巢癌患者(SOLO2/ENGOT-Ov21):一项双盲随机对照Ⅲ期试验的最终分析显示文摘背景既往发表的SOLO2/ENGOT-Ov21试验的第一部分研究结果表明,作为BRCA1或BRCA2(BRCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者总生存期的影响。方法本研究是一项在16个国家123个医疗中心进行的双盲、随机、安慰剂对照、Ⅲ期临床试验。纳入标准包括:年龄≥18岁;ECOG体能状态评分基线水平为0~1分;组织学检查确诊为复发性、高级别浆液性或高级别子宫内膜样卵巢癌,包括原发性腹膜癌或输卵管癌;以及既往接受过2种或2种以上铂类药物的治疗方案。入选患者按2∶1分配到奥拉帕利组(150 mg片剂,每日2次口服,共300 mg)或安慰剂组;根据既往化疗后是否缓解以及无铂治疗间隔时长进行分层;受试者、治疗提供者和数据分析人员在治疗分配时均设盲。主要终点是既往已报道过的无进展生存期;总生存期作为重要的次要终点之一,在所有随机分配的患者中进行分析;安全性评估在至少接受过1次给药的所有患者中进行。结果2013年9月3日—2014年11月21日,共295例患者参与了试验并被随机分到奥拉帕利组(196例,66%)或安慰剂组(99例,34%)治疗。奥拉帕利组患者中位随访时间为65.7个月(IQR:63.6~69.3),安慰剂组为64.5个月(IQR:63.4~68.7)。奥拉帕利组中位总生存期为51.7个月(95%CI:41.5~59.1),安慰剂组为38.8个月(95%CI:31.4~48.6)(HR=0.74,95%CI:0.54~1.00,P=0.054)。安慰剂组38%接受PARP抑制剂治疗的患者未作调整。治疗引发的最常见的Ⅲ级以上不良事件为贫血,奥拉帕利组发生率为21%(41/195),安慰剂组为2%(2/99)。 | Andrés Poveda Anne Floquet Jonathan A Ledermann Rebecca Asher Richard T Penson Amit M Oza Jacob Korach Tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni Tjoung-Won Park-Simon Kenji Tamura Gabe S Sonke Alla Lisyanskaya Jae-Hoon Kim Elias Abdo Filho Tsveta Milenkova Elizabeth S Lowe Phil Rowe Ignace Vergote Eric Pujade-Lauraine the SOLO/ENGOT-Ovinvestigators 王娟(校) 李征(校) | 2021 | 肿瘤药学2021，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员